Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients

American Journal of Transplantation

Volumn 12, Issue 7, 2012, Pages 1929-1935

  Luong, M L ^a   Hosseini Moghaddam, S M ^a   Singer, L G ^b   Chaparro, C ^b   Azad, S ^b   Lazar, N ^c   Boutros, P C ^d   Keshavjee, S ^b   Rotstein, C ^a   Husain, Shahid ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

Hepatotoxicity; Lung; Toxicity; Transplantation; Voriconazole

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; COTRIMOXAZOLE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VALGANCICLOVIR; VORICONAZOLE;

ACCURACY; ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBIOTIC PROPHYLAXIS; APACHE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIARY CIRRHOSIS; BILIRUBIN BLOOD LEVEL; BLOOD TRANSFUSION; BYPASS SURGERY; CANDIDEMIA; CHOLECYSTITIS; CHOLELITHIASIS; CONTROLLED STUDY; CORRELATIONAL STUDY; CYSTIC FIBROSIS; DRUG WITHDRAWAL; EARLY INTERVENTION; FEMALE; GENDER; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS C; HUMAN; LENGTH OF STAY; LIVER DISEASE; LIVER TOXICITY; LOADING DRUG DOSE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MYCOSIS; NAUSEA; NONALCOHOLIC FATTY LIVER; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; SCLEROSING CHOLANGITIS; SIDE EFFECT; TREATMENT WITHDRAWAL; VISUAL DISORDER;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; FEMALE; HUMANS; LIVER; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PYRIMIDINES; RETROSPECTIVE STUDIES; RISK FACTORS; TRIAZOLES; YOUNG ADULT;

EID: 84863184361     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04042.x     Document Type: Article

References (22)

1. Westney GE, Kesten S, De Hoyos A, Chapparro C,Winton T,Maurer JR. Aspergillus infection in single and double lung transplant recipients. Transplantation 1996; 61: 915-919. (Pubitemid 26107428)
2. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360. (Pubitemid 351265310)
3. Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6: 3008-3016.
4. Neoh CF, Snell GI, Kotsimbos T, et al. Antifungal prophylaxis in lung transplantation - A world-wide survey. Am J Transplant 2011; 11: 361-366.
5. Cadena J, Levine DJ, Angel LF, et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: Hepatotoxicity and effectiveness. Am J Transplant 2009; 9: 2085-2091.
6. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious DiseasesMycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
7. Colombo C, Battezzati PM, Crosignani A, et al. Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome. Hepatology 2002; 36: 1374-1382. (Pubitemid 35403528)
8. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: A review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005; 44: 1009-1034. (Pubitemid 41356389)
9. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-571. (Pubitemid 34165316)
10. Ueda K, Nannya Y, Kumano K, et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 2009; 89: 592-599.
11. Potoski BA, Brown J. The safety of voriconazole. Clin Infect Dis 2002; 35: 1273-1275.
12. Miyakis S, van Hal SJ, Ray J, Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect 2010; 16: 927-933.
13. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35: 509-513. (Pubitemid 40403355)
14. Kim SH, Yim DS, Choi SM, et al. Voriconazole-related severe adverse events: Clinical application of therapeutic drug monitoring in Korean patients. Int J Infect Dis 2011; 15: e753-e758.
15. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006; 46: 235-243. (Pubitemid 43146453)
16. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-211. (Pubitemid 351269158)
17. Harrell FEJ. Regression modeling strategies. New York: Springer, 2001.
18. Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 2011; 55: 4782-4788.
19. Levin MD, den Hollander JG, van der Holt B, et al. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J Antimicrob Chemother 2007; 60: 1104-1107. (Pubitemid 47617761)
20. den Hollander JG, van Arkel C, Rijnders BJ, Lugtenburg PJ, de Marie S, Levin MD. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. J Antimicrob Chemother 2006; 57: 1248-12450.
21. Chamilos G, Luna M, Lewis RE, Chemaly R, Raad, II, Kontoyiannis DP. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: A retrospective, nonrandomized autopsy study. Clin Ther 2007; 29: 1980-1986. (Pubitemid 350212807)
22. Bruggemann RJ, Donnelly JP, Aarnoutse RE, et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit 2008; 30: 403-411.